Currently Viewing:
Newsroom
Currently Reading
What We're Reading: Biden Will Announce Launch of Open-Access Cancer Database
June 06, 2016 – AJMC Staff
Study Associates High BMI With Risk of Aggressive Prostate Cancer
June 03, 2016 – Surabhi Dangi-Garimella, PhD
What We're Reading: Florida Cracks Down on Opioids, Reduces Prescriptions
June 03, 2016 – AJMC Staff
Canagliflozin Trial Finds Increased Risk of Amputations
June 02, 2016 – Jessica Men
Cigna, Anthem Take Steps to Curb the National Drug Epidemic
June 02, 2016 – Jackie Syrop
First Liquid Biopsy Companion Diagnostic, for Erlotinib, Approved by FDA
June 02, 2016 – Surabhi Dangi-Garimella, PhD
What We're Reading: Medicaid Can Pay for Mosquito Repellent to Fight Zika Spread
June 02, 2016 – AJMC Staff
FDA Proposes Lower Sodium Levels for Processed Foods
June 01, 2016 – Mary Caffrey
DSH Hospitals More Prone to Readmissions Following Cancer Surgery
June 01, 2016 – Surabhi Dangi-Garimella, PhD

What We're Reading: Biden Will Announce Launch of Open-Access Cancer Database

AJMC Staff
What we're reading, June 6, 2016: Vice President Joe Biden will announce the launch of an open-access cancer research database, and a new bill in Congress would allow companies to repurpose existing drugs for rare diseases.
An open-access cancer database for researchers will contain raw genomic and clinical data for 12,000 patients, initially. According to The Washington Post, the Genomic Data Commons will continue to add records as researchers contribute to it and will include data on the molecular makeup of cancers, which treatments were used and how the patients responded. Vice President Joe Biden, head of the Obama administration’s cancer moonshot initiative, has warned that research silos slow progress and that open access to data is critical.

A new bill in Congress would allow companies to repurpose existing drugs for rare diseases, which will be quicker and more economical that starting from scratch.  The OPEN ACT (Orphan Product Extensions Now Accelerating Cures and Treatments) could potentially double the number of treatment options available to the 30 million Americans affected by 7000 rare diseases, according to an opinion piece published in The Seattle Times. With FDA oversight, the legislation would make therapies safely available to people who need them instead of prescribing therapies “off-label.”

 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up